title: ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery.
abstract: OBJECTIVE
  Investigate ErbB family expression in colorectal cancer patients with higher risk of recurrence after surgical treatment.
  
  
  METHODS
  We studied 109 individuals with high risk stage II and stage III patients submitted to radical surgery. ErbB expression was assessed by tissue microarray technique.
  
  
  RESULTS
  The immunohistochemical expression was considered positive for EGFR, ErbB2, ErbB3, ErbB4 membrane, and ErbB4 cytoplasmic in respectively 57.8%, 8.3%, 69.7%, 11%, and 19.3% of patients. ErbB3 negative expression was associated with lymphovascular invasion. EGFR, ErbB2, and cytoplasmic ErbB4 expression was not associated with prognosis. Membranous positive ErbB4 expression was an independent prognostic factor for recurrence. ErbB3 negative expression was an independent prognostic factor for recurrence and survival in the multivariate analysis.
  
  
  CONCLUSIONS
  The immunohistochemical expression of ErbB3 and ErbB4 may identify a subgroup with stage II and III colorectal cancer at higher risk of recurrence.
authors.affiliation: Department of Gynecologic Oncology, Hospital do Cancer AC Camargo, 01509-010 Sao Paulo, Brazil. glbaiocchi@yahoo.com.br
authors.forename: Glauco
authors.initials: G
authors.lastname: Baiocchi
authors.forename: Ademar
authors.initials: A
authors.lastname: Lopes
authors.forename: Renata A
authors.initials: RA
authors.lastname: Coudry
authors.forename: Benedito M
authors.initials: BM
authors.lastname: Rossi
authors.forename: Fernando A
authors.initials: FA
authors.lastname: Soares
authors.forename: Samuel
authors.initials: S
authors.lastname: Aguiar
authors.forename: Gustavo C
authors.initials: GC
authors.lastname: Guimarães
authors.forename: Fabio O
authors.initials: FO
authors.lastname: Ferreira
authors.forename: Wilson T
authors.initials: WT
authors.lastname: Nakagawa
mesh_terms: D000368:Aged; D015179:Colorectal Neoplasms / Q000473:pathology* / Q000601:surgery; D003593:Cytoplasm / Q000737:chemistry; D013505:Digestive System Surgical Procedures; D066246:ErbB Receptors / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D042601:Lymphatic Vessels / Q000473:pathology; D008297:Male; D008565:Membrane Proteins / Q000032:analysis; D008875:Middle Aged; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D020893:Receptor, ErbB-3 / Q000032:analysis; D066247:Receptor, ErbB-4; D012008:Recurrence; D012306:Risk
chemical_list: D066246:ErbB Receptors; D008565:Membrane Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D020893:Receptor, ErbB-3; D066247:Receptor, ErbB-4; C512478:EGFR protein, human; C587689:ERBB4 protein, human